TYLENOL WITH CODEINE NO. 2 - TAB TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CODEINE PHOSPHATE; CAFFEINE; ACETAMINOPHEN

Saadav alates:

JANSSEN INC

ATC kood:

N02AJ06

INN (Rahvusvaheline Nimetus):

CODEINE AND PARACETAMOL

Annus:

15MG; 15MG; 300MG

Ravimvorm:

TABLET

Koostis:

CODEINE PHOSPHATE 15MG; CAFFEINE 15MG; ACETAMINOPHEN 300MG

Manustamisviis:

ORAL

Ühikuid pakis:

500

Retsepti tüüp:

Narcotic (CDSA I)

Terapeutiline ala:

OPIATE AGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0311391001; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2020-09-25

Toote omadused

_~db5_O33947f74e3dd4b8cbc967bc45698f0af.docx _
_ _
_EDMS-RIM-569056 v2.0 _
_Page 1 of 40 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TYLENOL
® WITH CODEINE NO. 2
acetaminophen, caffeine and codeine phosphate tablets
300 mg acetaminophen, 15 mg caffeine and 15 mg codeine phosphate
tablets
N
TYLENOL
® WITH CODEINE NO. 3
acetaminophen, caffeine and codeine phosphate tablets
300 mg acetaminophen, 15 mg caffeine and 30 mg codeine phosphate
tablets
Analgesic-Antipyretic
Janssen Inc.
200 Whitehall Drive
Markham, Ontario
L3R 0T5
www.janssen.com/canada
Date of Revision:
December 1, 2021
SUBMISSION CONTROL NO: 258437
All trademarks used under license.
© 2021 Janssen Inc.
_~db5_O33947f74e3dd4b8cbc967bc45698f0af.docx _
_ _
_EDMS-RIM-569056 v2.0 _
_Page 2 of 40 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................3
WARNINGS AND PRECAUTIONS
.............................................................................5
ADVERSE
REACTIONS............................................................................................
15
DRUG INTERACTIONS
............................................................................................
17
DOSAGE AND ADMINISTRATION
.........................................................................
18
OVERDOSAGE
.........................................................................................................
21
ACTION AND CLINICAL
PHARMACOLOGY.........................................................
24
STORAGE AND STABILITY
....................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
..................................................